Targeting Angiogenesis in Thyroid Cancer

Author(s): S. Lkhoyaali, S. Benhmida, M. Aitelhaj, M. Layachi, H. Abahssain, H.N. Ismaili, H. Errihani

Journal Name: Current Angiogenesis (Discontinued)

Volume 3 , Issue 2 , 2014

Graphical Abstract:


Thyroid cancers are characterized by a good prognosis but 10 to 15% of patients progress and become refractory to current therapies. Systemic treatment based on chemotherapy in these settings has shown limited efficacy, with response rates not exceeding 25%. At progression, differentiated thyroid cancer is characterized by a high level of expression of vascular endothelial growth factor (VEGF). This high expression of VEGF is associated with an aggressive tumor behavior and a poor clinical outcome.

We will review the recent advances in targeting angiogenesis in the treatment of recurrent and metastatic thyroid carcinoma.

Keywords: Angiogenesis, targeted therapy, thyroid cancer.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 08 January, 2015
Page: [107 - 112]
Pages: 6
DOI: 10.2174/2211552802666140716170521
Price: $58

Article Metrics

PDF: 10